Press Releases

HINGHAM, Mass., Feb. 6, 2020 /PRNewswire/ -- Wellness Workdays, a leading provider of worksite wellness programs, will host its 7th Annual Emerging Trends in Wellness Conference on April 1-2. The event, which will be held at Granite Links outside of Boston, will feature nationally-recognized

TEL AVIV, Israel, Feb. 6, 2020 /PRNewswire/ -- Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that an Extraordinary General Meeting of Shareholders will be held on Thursday, March 12, 2020 at 9:30 a.m. (Israel time), at the office of Go

NEW HAVEN, Conn., Feb. 6, 2020 /PRNewswire/ -- Kleo Pharmaceuticals, Inc., an immuno-oncology company developing next-generation, fully synthetic bispecific compounds des

CRANBURY, N.J., Feb. 6, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2020 operating results on Tuesday, February 11, 2020 before the open of the U.S. financial markets.

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Feb. 6, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company" ), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patie

Amir Hadanny, MD, Chief Medical Research Officer of The Sagol Center for Hyperbaric Medicine and Research, to discuss innovative approaches to aging treatment TEL AVIV, Israel,

ORLANDO, Fla., Feb. 6, 2020 /PRNewswire/ -- Amy Lung, COO of HealthMine, will moderate a panel on Thursday, February 6th at

COLUMBUS, Ohio, Feb. 6, 2020 /PRNewswire/ -- Two Labs, an industry-leading pharma services company, today announced that it has acquired CEEK Enterprises, a management consultancy dedicated to supporting clients in the biopharma and MedTech industries with specialized expertise in corporate development, commercial strategy, clinical development and medical affairs.

VANCOUVER, Feb. 6, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that the Series A convertible voting preferred stock issued

OLDWICK, N.J., Feb. 6, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today highlighted several new research studies on the increasing prevalence of type one diabetes (T1D) and the importance of screening for this life-impacting and life-threaten